Bu Yin

Bu Yin is a counsel in Goodwin’s nationally recognized Life Sciences group and focuses on patent portfolio development and strategies.

Building on his molecular biology and immunology background, Bu works closely with companies developing RNA therapeutics (e.g., mRNAs, trans-splicing RNAs, and siRNAs), antisense oligonucleotides (e.g., exon skipping), therapies involving gene editing or epigenome editing, gene therapies (e.g., using HSV, AAV, or non-viral vectors), cell therapies (e.g., CAR-T and stem cells), antibody therapeutics, vaccines, and antibiotics, among other therapeutic modalities.

Bu also has significant experience in medical devices (e.g., self-navigation endoscopes, balloon catheters, vein ablation devices, autoinjectors, and intraocular implants); life science tools (e.g., DNA sequencing, protein sequencing, spatial, in situ, and single-cell assays, PCRs, analyte encoding/decoding, and multi-omics data analytics); diagnostics (e.g., liquid biopsy); and agriculture technologies (e.g., genetically modified insects as biopesticides).

Bu’s practice integrates patent prosecution, litigation support, and IP due diligence in connection with venture capital and private and public financing. For instance, he supported litigation involving technologies such as antibody engineering, transgenic plants as host for producing human proteins, enzyme replacement therapies, cancer diagnostics, nucleic acid sequencing, and chromatography techniques. Drawing upon these experiences, Bu aims to maximize value in IP for companies at different stages and provides pragmatic advice with future enforcement and litigation risks in mind.

Bu’s recent representative experience includes:

• Freedom-to-operate (FTO) analysis of GLP-1, GLP-1/GIP, and GLP-1/GIP/glucagon agonists
• Portfolio development for a startup company developing therapeutics to reverse the underlying drivers of aging and chronic diseases
• Patent application drafting and prosecution relating to artificial intelligence (AI) and machine learning (ML) in disease diagnosis and drug development
• IP due diligence for an investment firm in connection with its investments in a company developing next-generation siRNA therapeutics for treating cardiometabolic diseases and in a company developing circular RNA therapeutics and vaccines*
• IP due diligence, including extensive loss of exclusivity (LoE) analysis, for a pharmaceutical company in its ~$5 billion acquisition of immune checkpoint inhibitor assets*
• Patent Term Extension (PTE) application for a clinical-stage company developing gene therapies for dermatology, oncology, and pulmonology indications*
• IPO, cross-border R&D collaboration, and patent application drafting and prosecution for a multinational biopharmaceutical company developing immuno-oncology and vaccine products*
• Patent application drafting and prosecution relating to small molecules including a KRAS G12C inhibitor approved in China, and NLRP3 inflammasome inhibitors and Nav1.8 inhibitors in clinical development*
• Patent application drafting and prosecution for a company mapping brain circuits and connectomics at the scale of whole mammalian brains*
• Patent prosecution for global biopharma companies relating to kinase inhibitors, checkpoint inhibitors, cytokines, small peptide therapeutics, TCR-like antibodies, diagnostic and prognostic biomarkers, glyco-engineered therapeutics, personalized medicine, and various combination therapies*
• All aspects of patent counseling for a company developing soft robotic endoscopy products*
• All aspects of patent counseling for a company developing ophthalmic surgical devices, drug formulations, and companion diagnostics*
• Strategies for interference proceeding, European opposition, and inter partes review involving nucleic acid sequencing chemistry, library preparation, and assay formats*
• Litigation support for a case involving non-competitive immunoassays for small analytes*
• Litigation support for a case involving long-acting C5 complement antibodies for treating thrombotic diseases*
• Litigation support for a case involving recombinant production and chromatographic purification of therapeutic proteins from plants*

*Denotes experience prior to joining Goodwin

• SoCal Association for Biomedical and Pharmaceutical Advancements (SABPA)
• National Asian Pacific American Bar Association (NAPABA)

• Ones to Watch, Intellectual Property Law, by Best Lawyers in America (Sixth Edition)
• Ones to Watch, Patent Law, by Best Lawyers in America (Sixth Edition)
• Ones to Watch, Life Sciences Practice, by Best Lawyers in America (Sixth Edition)
• Saul Winegrad Award for Outstanding Dissertation, University of Pennsylvania (2010)
• Emphasis Pathway in Tumor Immunology Grant from the Cancer Research Institute (2008-2010)

Select Publications

• Co-author, “Inhibition of precursor B-cell malignancy progression by toll-like receptor ligand-induced immune responses,” Leukemia, 30(10):2116-2119, 2016
• Co-author, “Histone H2AX suppresses translocations in lymphomas of Eμ-c-Myc transgenic mice that contain a germline amplicon of tumor-promoting genes,” Cell Cycle, 12:2867-75, 2013
• Co-author, “ATM deficiency augments constitutively nuclear cyclin D1-driven genomic instability and lymphomagenesis,” Oncogene, 33(1):129-33, 2013
• First author, “Redundant and nonredundant functions of ATM and H2AX in αβ T-lineage lymphocytes,” Journal of Immunology, 189:1372-9, 2012
• First author, “Cellular context dependent effects of H2ax and p53 deletion upon the development of thymic lymphoma,” Blood, 117:75-85, 2011
• Co-author, “Distinct roles for PTEN in prevention of lymphoma and autoimmunity,” Journal of Clinical Investigation, 120:2497-507, 2010
• First author, “H2AX suppresses chromosome end separation and subsequent break/translocation formation in V(D)J recombination,” Journal of Experimental Medicine, 206:2625-39, 2009
• Co-author, “Formation of dynamic gamma-H2AX structures along broken DNA strands is distinctly regulated by ATM and MDC1 and dependent upon H2AX densities in chromatin,” Molecular Cell, 34:298-310, 2009
• Co-first author, “RAG1 and ATM co-ordinate mono-allelic recombination and nuclear positioning of Ig loci,” Nature Immunology, 10:655-64, 2009
• First author, “V(D)J Recombination causes dangerous chromosome liaisons in developing thymocytes,” Cell Cycle, 8:2486-7, 2009
• First author, “The sticky business of H2AX in V(D)J recombination, maintenance of genomic stability, and suppression of lymphoma,” Immunologic Research, 42:29-40, 2008
• First author, “ATM prevents unattended DNA double strand breaks on site and in generations to come,” Cancer Biology & Therapy, 6:1837-9, 2007

Select Speaking Engagements

• Panelist, “Roundtable: Rethinking Biotech-Pharma Deals in a Shifting Landscape,” Global Forum on Innovation and Investment in Advanced Medical Technologies, Orange County, CA, 2025
• Speaker, “Creating Value in and Through IP Portfolios in Challenging Times,” Sino-American Pharmaceutical Professionals Association - New England/Boston (SAPA-NE) 25th Annual Conference: Poised to Pivot - Build Resilience in a Challenging Market, Cambridge, MA, 2023